Contribution of different relapse phenotypes to disability in multiple sclerosis

T Stewart; T Spelman; E Havrdova; D Horakova; M Trojano; G Izquierdo; P Duquette; M Girard; A Prat; A Lugaresi; F Grand'Maison; P Grammond; P Sola; V Shaygannejad; R Hupperts; R Alroughani; C Oreja-Guevara; E Pucci; C Boz; J Lechner-Scott; R Bergamaschi; V Van Pesch; G Iuliano; C Ramo; B Taylor; M Slee; D Spitaleri; F Granella; F Verheul; P McCombe; S Hodgkinson; MP Amato; S Vucic; O Gray; E Cristiano; M Barnett; JL Sanchez Menoyo; E Van Munster; ML Saladino; J Olascoaga; J Prevost; N Deri; C Shaw; B Singhal; F Moore; C Rozsa; N Shuey; O Skibina; I Kister; T Petkovska-Boskova; R Ampapa; A Kermode; H Butzkueven; V Jokubaitis; T Kalincik

Journal article

Contribution of different relapse phenotypes to disability in multiple sclerosis

T Stewart, T Spelman, E Havrdova, D Horakova, M Trojano, G Izquierdo, P Duquette, M Girard, A Prat, A Lugaresi, F Grand'Maison, P Grammond, P Sola, V Shaygannejad, R Hupperts, R Alroughani, C Oreja-Guevara, E Pucci, C Boz, J Lechner-Scott Show all

Multiple Sclerosis | Published : 2017

DOI: 10.1177/1352458516643392

Abstract

Objective: This study evaluated the effect of relapse phenotype on disability accumulation in multiple sclerosis. Methods: Analysis of prospectively collected data was conducted in 19,504 patients with relapse-onset multiple sclerosis and minimum 1-year prospective follow-up from the MSBase cohort study. Multivariable linear regression models assessed associations between relapse incidence, phenotype and changes in disability (quantified with Expanded Disability Status Scale and its Functional System scores). Sensitivity analyses were conducted. Results: In 34,858 relapses recorded during 136,462 patient-years (median follow-up 5.9 years), higher relapse incidence was associated with greater..

View full abstract

University of Melbourne Researchers

Timothy Spelman Author

Neil Shuey Author

Tomas Kalincik Author

Related Projects (2)

CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Clinical Centre of Research Excellence in Translational Neuroscience will provide people, pathways and resources to create a novel platform ..

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was financially supported by National Health and Medical Research Council (practitioner fellowship 1080518, project grants 1083539 and 1032484 and centre for research excellence 1001216) and University of Melbourne (Faculty of Medicine, Dentistry and Health Sciences research fellowship). The MSBase Foundation is a not-for-profit organisation that receives support from Merck, Biogen, Novartis, Bayer Schering, Sanofi Aventis and BioCSL. The study was conducted separately and apart from the guidance of the sponsors.